Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5994027 | 0.78 | HSD17B10 (0.53) | HSD17B10KDM4ELMNAHTTMEN1 | |
| SCHEMBL5950941 | 0.78 | HSD17B10 (0.53) | HSD17B10KDM4ELMNAHTTMEN1 | |
| SCHEMBL12231813 | 0.78 | GAA (0.54) | KDM4EHTTMEN1KMT2AGAA | |
| SCHEMBL24781224 | 0.77 | FABP6 (0.49) | HTTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL10140553 | 0.77 | GAA (0.34) | HTTGAA | |
| SCHEMBL13188083 | 0.77 | KDM4E (0.51) | HSD17B10KDM4ELMNAHTTMEN1 | |
| SCHEMBL18949114 | 0.75 | KDM4E (0.50) | HSD17B10KDM4ELMNAHTTMEN1 | |
| SCHEMBL12438207 | 0.74 | ALDH1A1 (0.42) | HSD17B10KDM4EHTTALDH1A1ALOX15 | |
| SCHEMBL12938095 | 0.73 | KDM4E (0.69) | HSD17B10KDM4ELMNAHTTMEN1 | |
| SCHEMBL10141265 | 0.72 | ALDH1A1 (0.60) | HSD17B10KDM4ELMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885KDM4E 1193/4885LMNA 2800/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885KDM4E 1193/4885LMNA 2800/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | HSD17B10 1474/4885KDM4E 1321/4885LMNA 886/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885KDM4E 1193/4885LMNA 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.